Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

24.97 -0.19 (-0.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
19 20 Next >
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday, 27 stocks hit new 52-week lows. 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Apellis Pharmaceuticals Stock Slips Despite Q2 Sales Beat Thanks To Syfovre, Empaveli ↗
Apellis Pharmaceuticals Inc (NASDAQ: APLS) reported a second quarter (Q2) EPS loss of $1.02, beating the  
Via Benzinga
News headline image
Where Apellis Pharmaceuticals Stands With Analysts ↗
 
Via Benzinga
News headline image
Rising Stars, Falling Trends: July's Industry ETF Winners And Losers ↗
 
Via Benzinga
News headline image
Why China Natural Resources Shares Are Trading Higher By Around 64%; Here Are 20 Stocks Moving Premarket ↗
Gainers 
Via Benzinga
News headline image
Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For July 31, 2023 ↗
Companies Reporting Before The Bell • Immunogen (NASDAQ:IMGN) is estimated to report quarterly loss at $0.16 per share on revenue of $42.84 million. 
Via Benzinga
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
News headline image
Alphabet, Boeing, Union Pacific And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded mixed, with the Dow Jones gaining around 50 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
News headline image
Tarsus Pharma Shares Under Pressure: Analyst Says Concerns Over Adverse Event Profile Overblown ↗
The FDA approved Tarsus Pharmaceuticals Inc's (NASDAQ: TARS) Xdemvy (lotilaner ophthalmic solution) 0.25% for  
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
News headline image
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
From Apellis Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Dow Jones Leads Market Advance As Tesla, Netflix, Taiwan Semiconductor Hit Growth: Weekly Review ↗
But all the major indexes are at or near 15-month highs. 
Via Investor's Business Daily
News headline image
APLS Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Investors
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  During Thursday's session, 40 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Apellis's Stock Under Pressure On Syfovre Safety Concerns: Analyst Slashes Price Target ↗
Since Friday, Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares have plummeted around 50% after the stock came under pressure following the disclosure of  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – APLS
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday's trading, 46 companies set new 52-week lows. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring. 
Via Benzinga
News headline image
Why Are Apellis Pharmaceuticals Shares More Down 20% Today? ↗
Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower amid safety concerns regarding the company's newly launched Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.